The weight loss peptide landscape shifted dramatically in March 2026. TRIUMPH-4, the Phase 3 pivotal trial for retatrutide, reported its primary endpoints — and the numbers stunned even optimistic researchers. Participants lost an average of 71.2 lbs (32.3 kg) over 48 weeks, representing roughly 28–30% of total body weight. For context, that is nearly double what semaglutide achieves and meaningfully ahead of tirzepatide's landmark SURMOUNT-1 results. If you are trying to figure out which GLP-1 compound deserves your attention right now, this is the article to read first.
How Each Compound Works: The Receptor Mechanism
All three compounds act on overlapping but distinct receptor profiles. Understanding the differences explains why efficacy scales up so dramatically from semaglutide to tirzepatide to retatrutide.
| Compound | GLP-1 Receptor | GIP Receptor | Glucagon Receptor | Mechanism Class |
|---|---|---|---|---|
| Semaglutide | Yes (primary) | No | No | GLP-1 RA (mono) |
| Tirzepatide | Yes | Yes (primary) | No | GIP/GLP-1 dual agonist |
| Retatrutide | Yes | Yes | Yes (added) | GIP/GLP-1/glucagon triple agonist |
The glucagon receptor addition in retatrutide is the key differentiator. Glucagon agonism increases energy expenditure directly — the liver burns more fat at rest. Combined with GLP-1's appetite suppression and GIP's insulin sensitization, the triple mechanism creates a synergistic effect that neither mono nor dual agonists can match. This is not incremental; it is a category leap.
Head-to-Head Clinical Data
These are the pivotal trial results for each compound. Note that cross-trial comparisons have limitations — populations and protocols differ — but the magnitude of difference is large enough to be clinically meaningful regardless of methodological variability.
| Compound | Trial | Duration | Mean Weight Loss | Max Dose |
|---|---|---|---|---|
| Semaglutide | STEP-1 | 68 weeks | 14.9% body weight | 2.4 mg/week SC |
| Tirzepatide | SURMOUNT-1 | 72 weeks | 22.5% body weight | 15 mg/week SC |
| Retatrutide | TRIUMPH-4 (Phase 3) | 48 weeks | ~28–30% body weight | 12 mg/week SC |
The TRIUMPH-4 48-week timeframe is notably shorter than the other trials, yet retatrutide's weight loss exceeds both predecessors. Extrapolated to 68–72 weeks, some analysts project the final plateau could reach 33–35% body weight reduction for high responders. The dose-response curves in Phase 2 showed no clear plateau at 12 mg, suggesting even higher doses may be explored in future trials.
The Dysesthesia Safety Signal: What You Need to Know
Retatrutide's extraordinary efficacy comes with a safety signal that was not prominent in earlier GLP-1 compounds: dysesthesia — abnormal skin sensations including numbness, tingling, burning, and crawling sensations. In TRIUMPH-4, the incidence ranged from 8.8% at lower doses to 20.9% at the highest dose cohort. Most cases were mild to moderate and resolved without discontinuation, but approximately 3% of participants withdrew due to the symptom.
The mechanism is not fully understood. Leading hypotheses include direct glucagon receptor activity in peripheral nerve tissue and transient changes in electrolyte balance during rapid fat mobilization. The FDA has flagged dysesthesia as a required monitoring parameter in the NDA submission. For now, it is the primary reason some physicians advise waiting for real-world post-approval data before adopting retatrutide at maximum doses.
Other Side Effects: How They Compare
- GI effects (nausea, vomiting, diarrhea): All three compounds share this class effect. Retatrutide GI rates are comparable to tirzepatide at equivalent efficacy doses.
- Injection site reactions: Minor across all three; no significant differences in Phase 3.
- Gallbladder disease: A known GLP-1 class risk, elevated in rapid weight losers. Risk is proportionally higher with retatrutide given the speed of fat loss.
- Muscle loss: Rapid weight loss increases lean mass loss risk. Protein targets of 1.6–2.2g/kg/day and resistance training are strongly advised for all three compounds.
Regulatory Status in 2026
Understanding where each compound stands legally is essential for anyone making sourcing decisions.
- Semaglutide (Ozempic, Wegovy): FDA-approved for T2D (2017) and obesity (2021). Widely available via prescription. Compounded versions remain available in some markets pending FDA enforcement actions.
- Tirzepatide (Mounjaro, Zepbound): FDA-approved for T2D (2022) and obesity (2023). Prescription access is broad; compounding availability depends on shortage designation status.
- Retatrutide: Phase 3 complete as of early 2026. NDA submission expected Q2 2026. Earliest plausible FDA approval: late 2027 to 2028. Currently available only through research/gray market channels.
The gray market availability of retatrutide is real — research peptide suppliers have offered it since Phase 2 data emerged — but regulatory status and quality control vary enormously. Anyone sourcing retatrutide outside clinical trials should prioritize verified third-party testing for purity, sterility, and correct peptide sequence.
Who Should Use Which Compound?
Semaglutide: Best for Beginners and T2D Management
Semaglutide is the most studied compound with the longest real-world safety record. It is the right starting point for people new to GLP-1 therapy, those with type 2 diabetes where approved GLP-1 RAs are indicated, and individuals who want the most conservative risk profile. The 14.9% weight loss is still clinically significant — enough to meaningfully reduce cardiovascular risk and improve metabolic markers.
Tirzepatide: Best Approved Option for Maximum Efficacy
For people who want the most efficacious FDA-approved compound available today, tirzepatide is the answer. The 22.5% weight loss in SURMOUNT-1 represents a step-change from semaglutide, and the dual GIP/GLP-1 mechanism provides better insulin sensitivity benefits. It is now widely available via prescription and has two years of growing real-world safety data. This is the compound most obesity medicine physicians will reach for first in 2026.
Retatrutide: Advanced Users Willing to Accept Higher Uncertainty
Retatrutide is for those who want the highest available efficacy, understand they are operating outside approved indications, and are willing to monitor carefully for dysesthesia and other emerging signals. Given its regulatory timeline, most people with access will be using gray market research-grade product for at least 18–24 more months. That is not inherently disqualifying, but it demands rigorous sourcing standards and ideally physician involvement.
Retatrutide wins on raw efficacy — 28–30% body weight loss in 48 weeks is unprecedented. But "winning" on a Phase 3 number is not the same as being the right choice for every person. Semaglutide is the safe beginner play. Tirzepatide is the approved efficacy leader. Retatrutide is for those who want the absolute ceiling and accept the trade-offs. All three work. The question is how much efficacy you need, how much risk you are willing to accept, and what your regulatory access looks like.
For a detailed comparison chart covering mechanism, dosing protocols, side effect profiles, cost, and sourcing considerations, see our complete GLP-1 comparison guide.
Product Links
If you are ready to explore these compounds further, we carry third-party tested research-grade peptides: